Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 9/20 | 0.62 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | NSD2 | O96028 | 6/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.47 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2419326 | 0.92 | SSTR5 (0.53) | SSTR5APPNSD2HRH1HTR2B | |
| SCHEMBL2418134 | 0.91 | SSTR5 (0.61) | SSTR5APPNSD2HRH1HTR2B | |
| SCHEMBL2416953 | 0.89 | SSTR5 (0.62) | SSTR5APPNSD2HRH1HTR2B | |
| SCHEMBL2413836 | 0.88 | EHMT2 (0.58) | SSTR5APPNSD2HRH1HTR2B | |
| SCHEMBL2420413 | 0.88 | APP (0.53) | SSTR5APPNSD2HRH1HTR2B | |
| SCHEMBL2418313 | 0.88 | SSTR5 (0.64) | SSTR5APPNSD2HRH1HTR2B | |
| SCHEMBL2416160 | 0.85 | SSTR5 (0.50) | SSTR5APPNSD2HRH1HTR2B | |
| SCHEMBL1748836 | 0.83 | SSTR5 (0.62) | SSTR5APPHRH1HTR2BACHE | |
| SCHEMBL2417624 | 0.82 | SSTR5 (0.51) | SSTR5NSD2HRH1HTR2B | |
| SCHEMBL1748889 | 0.82 | SSTR5 (0.61) | SSTR5APPNSD2HRH1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026255-B2 | Substituted piperidines as somatostatin receptor subtype 5 (SSTR5) antagonists | HOFFMAN-LA ROCHE INC. (US) | 2011-09-27 | — | — | US | claimed |
| US-20100222350-A1 | PHENYL, PYRIDINE, QUINOLINE, ISOQUINOLINE, NAPHTHYRIDINE AND PYRAZINE DERIVATIVES | BINGGELI ALFRED | 2010-09-02 | — | — | US | claimed |
| EP-2054385-A2 | PHENYL, PYRIDINE AND QUINOLINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-05-06 | — | — | EP | claimed |
| WO-2008019967-A2 | PHENYL, PYRIDINE AND QUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-21 | — | — | WO | claimed |
| US-20080045544-A1 | Phenyl, Pyridine, Quinoline, Isoquinoline, Naphthyridine and Pyrazine Derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-21 | — | — | US | claimed |
| US-8026255-B2 | Substituted piperidines as somatostatin receptor subtype 5 (SSTR5) antagonists | HOFFMAN-LA ROCHE INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20100222350-A1 | PHENYL, PYRIDINE, QUINOLINE, ISOQUINOLINE, NAPHTHYRIDINE AND PYRAZINE DERIVATIVES | BINGGELI ALFRED | 2010-09-02 | — | — | US | disclosed |
| US-7754744-B2 | Substituted piperidinamines as somatostatin receptor subtype 5 (SSTR5) antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-07-13 | — | — | US | disclosed |
| EP-2054385-A2 | PHENYL, PYRIDINE AND QUINOLINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008019967-A2 | PHENYL, PYRIDINE AND QUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-21 | — | — | WO | disclosed |
| US-20080045544-A1 | Phenyl, Pyridine, Quinoline, Isoquinoline, Naphthyridine and Pyrazine Derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222350-A1 | PHENYL, PYRIDINE, QUINOLINE, ISOQUINOLINE, NAPHTHYRIDINE AND PYRAZINE DERIVATIVES | SSTR5, SSTR3, SSTR1 | SSTR5 1/4885APP 1066/4885NSD2 3315/4885 |
| US-20080045544-A1 | Phenyl, Pyridine, Quinoline, Isoquinoline, Naphthyridine and Pyrazine Derivatives | SSTR5, SSTR3, SSTR1 | SSTR5 1/4885APP 1066/4885NSD2 3315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.